[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-metastatic-to-bone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-metastatic-to-bone":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100642906","patients-with-metastasized-prostate-cancer-whose-prostate-specific-antigen-level-psa-remains-02-ngml-after-six-months-of-dual-antihormonal-therapy-will-receive-radiotherapy-to-the-prostate-and-radiotherapy-to-refractory-metastases-100642906",false,"NCT07644754","Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng\u002Fml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases","RIALTO: Radiotherapy in Primarily Metastasized Prostate Cancer - Image-guided Local AbLaTion of Prostate and Oligoresidual Disease","RIALTO","Inclusion Criteria:\n\n* Prostate adenocarcinoma\n* de novo metastasized prostate cancer (at least 4 osseous metastases +\u002F- lymphonodal metastases)\n* first-line combined antihormonal therapy (ADT + ARPI) for six months\n* PSA \\> 0,2 ng\u002Fml after six months of combined ADT\u002FARPI therapy\n* multimetastasized disease stage without visceral metastases on imaging at first diagnosis (PET, CT, or bone scan)\n* \\\u003C16 osseous\u002Flymphnodal metastases on response assessment imaging (PSMA-PET\u002FCT) after six months of combined antihormonal therapy\n\nExclusion Criteria:\n\n* neuroendocrine histology\n* visceral metastases (M1c)\n* prior radiotherapy to the pelvis\n* PSA \\\u003C 0,2 ng\u002Fml after 6 months of combined antihormonal therapy\n* prior prostatectomy\n* contraindication against PSMA-PET\u002FCT and\u002For radiotherapy to the prostate\u002Fmetastases\n* HIFU or TUR-P within 6 months of study treatment\n* other active malignancy two years prior to study inclusion (except skin cancer in remission)\n* relevant GU\u002FGI condition (active fistula or other)\n* known tumor predisposition syndrome","MALE","18 Years","85 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if radiotherapy to the prostate and PET-positive (positron emission tomography) metastasis will lead to radiological response on PSMA-PET (prostate specific membrane antigen-PET). Patients who receive combined androgen deprivation therapy for de novo metastasized prostate cancer and show an incomplete PSA-response (\\>0,2 ng\u002Fml after six months) and exhibit at least four bone metastases on PET-imaging at this time point (without metastases to organs) can take part in this study.\n\nThe main questions it aims to answer are:\n\n• Does radiotherapy to the prostate and PET-positive metastases lead to a radiological response one year after radiotherapy? Researchers will analyze PET-imaging prior to radiotherapy to the prostate and metastases and one yeare thereafter.\n\nParticipants will:\n\n* Continue taking combined androgen-deprivation therapy\n* Receive a total of three PSMA-PET\u002FCT scans\n* Receive radiotherapy to the prostate and PET-positive metastases\n* Visit the clinic every three months for 36 months\n* Complete quality of life questionnaires at every visit",[28,29,30],"Prostate Cancer","Prostate Cancer Metastatic Disease","Prostate Cancer Metastatic to Bone",[32,33,34,35],"mHSPC","insufficient PSA-response to dual antihormonal treatment","local therapy","radiotherapy","NOT_YET_RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-12","ACTUAL",{"date":42,"type":22},"2026-07",{"date":44,"type":22},"2031-02",{"name":46,"class":47},"University Hospital Tuebingen","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100549161","outcomes-of-local-treatment-for-oligometastatic-prostate-cancer-diagnosed-using-psma-pet-imaging-oligomet-study-100549161","NCT06430411","Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study","OLIGOMET","Inclusion Criteria:\n\n* Oligometastatic prostate cancer diagnosed using PSMA PET defined as cM1a and\u002For cM1b with ≤5 osseous metastases and\u002For M1c with ≤3 lung lesions, with or without cN positivity.\n* Oligometastatic prostate cancer treated with primary local therapy such as radical prostatectomy or radiation therapy.\n* Any Gleason Score, any cT stage, any PSA\n\nExclusion Criteria:\n\n* Visceral metastases (apart from lungs).\n* Neoadjuvant therapy prior to first PSMA PET.\n* Non-metastatic prostate cancer.\n* Patients who did not undergo imaging before local treatment.","80 Years",{"count":57,"type":22},500,"5 Years","OBSERVATIONAL","PSMA-PET\u002FCT or PSMA-PET\u002FMRI are more accurate imaging modalities compared to CT\u002FBS; in approximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET up-stages the disease. Therefore a substantial proportion of high-risk patients previously considered as non-metastatic are expected to be diagnosed with oligometastatic disease. While standard treatment pathways exist for patients with non-metastatic or oligometastatic disease confirmed using conventional imaging, less is known about the optimal management of patients with oligometastatic prostate cancer on PSMA-PET.\n\nCurrently, data on the safety, effectiveness and oncologic outcomes of local therapies in oligometastatic patients diagnosed using PSMA-PET have been poorly reported so far. Thus, there is a need for a prospectively maintained database to collect real-world clinical data to produce high-quality research on the optimal management in oligometastatic prostate cancer who underwent PSMA-PET for primary staging and subsequent local therapy. This database will allow centers to retro- and prospectively collect data to facilitate analysis and assessment of the outcomes of oligometastatic patients managed with local therapy.",[62,30,28,63,64,65],"Prostate Cancer Metastatic","Prostate Neoplasm","Oligometastatic Disease","Oligometastasis",[67,68,69,70,71,72,73,74,75,76,77,78,79,80],"prostate","oligometastatic","oligometastasis","oligomet","prostatectomy","irradiation","abiraterone","enzalutamide","darolutamide","apalutamide","androgen deprivation therapy","ADT","docetaxel","PSMA PET","2024-05-24",{"date":83,"type":40},"2024-05-28",{"date":85,"type":22},"2024-05-31",{"date":87,"type":22},"2031-12-31",{"name":89,"class":47},"Medical University of Vienna"]